12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Company News  |  Other News

Momenta, Amphastar Pharmaceuticals, Watson cardiovascular, generics news

Momenta disclosed in its 3Q12 earning that in September it filed for an en banc rehearing of a decision by the U.S. Court of Appeals for the Federal Circuit (CAFC). In August, the CAFC vacated a preliminary injunction sought by generic enoxaparin maker Momenta that would have prevented Amphastar from selling its own version of the...

Read the full 258 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >